Sandia Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Sandia Biotech is a private, early-stage biotech firm commercializing a novel fluorescent reagent platform called FluorAbodies. These reagents are single-chain variable fragments (ScFvs) genetically fused to fluorescent proteins, designed to overcome limitations of conventional antibody conjugates in research and diagnostics. The company appears to be in an early commercial phase, generating revenue through direct sales of its catalog products, with a primary focus on oncology biomarkers like HER2 and EphA2. Leadership includes co-founder and President Tony Pino, though the full team is not detailed on the public website.

Oncology

Technology Platform

FluorAbody platform: recombinant single-chain variable fragments (ScFvs) genetically fused to fluorescent proteins, creating intrinsically fluorescent probes with a 1:1 fluorophore-to-epitope ratio for quantitative biomarker analysis.

Opportunities

The FluorAbody platform addresses major needs in the large research reagents and diagnostic antibodies markets by enabling quantitative, consistent, and simplified staining.

Successful entry into the clinical diagnostics space, particularly for established biomarkers like HER2 in breast cancer, represents a high-value regulatory and commercial pathway.

The technology's applicability for drug discovery and companion diagnostics opens partnership avenues with biopharma companies.

Risk Factors

The company faces intense competition from established giants in the research antibodies market and must overcome inertia to drive adoption of a novel platform.

Pursuing the clinical diagnostics opportunity requires navigating costly and time-intensive regulatory pathways (FDA/CE).

Limited public information on leadership, funding, and operational scale creates uncertainty about the company's execution capability and financial runway.

Competitive Landscape

Sandia Biotech competes in the broad research antibodies market against dominant players like Thermo Fisher Scientific, Abcam, Bio-Rad, and Cell Signaling Technology. Its differentiation is technological (quantitative, monovalent ScFv-fluorescent protein fusions), but it lacks the vast catalog and distribution reach of incumbents. In diagnostics, it would compete with IVD giants such as Roche, Agilent/Dako, and Abbott, who have entrenched positions and fully validated, regulated assay systems.

More companies in Biologics / Biosimilars →More companies in United States →